AmarinSTU:EH3 -0.70%54 Gross Margin % is 39.37% as of Mar. 2026, which is 47% below its 10-year median of 74.38. GuruFocus rates STU:EH3 with a GF Score™ of 54/100 and a GF Value™ of €10.19. The stock has 3 warning signs investors should review. Among 935 Drug Manufacturers companies, Amarin ranks better than 55.94% on this metric.
Gross Margin % is calculated as gross profit divided by its revenue. Amarin's Gross Profit for the
three
months ended in Mar. 2026 was €15.4 Mil. Amarin's Revenue for the
three
months ended in Mar. 2026 was €39.0 Mil. Therefore, Amarin's Gross Margin % for the quarter that ended in Mar. 2026 was 39.37%.
Warning Sign:
Amarin Corp PLC gross margin has been in long-term decline. The average rate of decline per year is -11.4%.
The historical rank and industry rank for Amarin's Gross Margin % or its related term are showing as below:
STU:EH3'
s Gross Margin % Range Over the Past 10 Years
Min: 35.6 Med: 74.38 Max: 79.2
Current: 52.37
During the past 13 years, the highestGross Margin % of Amarin was 79.20%. The lowest was 35.60%. And the median was 74.38%.
STU:EH3's Gross Margin % is ranked better than 55.94% of 935
companies
in the Drug Manufacturers industry
Industry Median: 48.46
vs STU:EH3: 52.37
Amarin had a gross margin of 39.37% for the quarter that ended in Mar. 2026 => Competition eroding margins
The 5-Year average Growth Rate of Gross Margin for Amarin was -11.40% per year.
Amarin (STU:EH3) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Amarin had a gross margin of 39.37% for the quarter that ended in Mar. 2026 => Competition eroding margins
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Amarin Gross Margin % Related Terms
Amarin Gross Margin % Historical Data
* Premium members only.
The historical data trend for Amarin's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:EH3 vs SCLX, MIRA, NSRX: Gross Margin % Comparison
For the Drug Manufacturers - General subindustry, Amarin's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amarin Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Amarin's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Amarin's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Amarin (STU:EH3) has a Gross Margin % of 39.37% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Amarin and its competitors. This is 47% below median its historical median of 74.38. Over the past decade, Amarin's Gross Margin % has ranged from 35.60 to 79.20. According to the industry distribution chart, Amarin ranks #412 out of 935 companies in the Drug Manufacturers industry, placing it in the top 44.1%.
Is Amarin's Gross Margin % too high?
Amarin's current Gross Margin % of 39.37% is 47% below median its 10-year median of 74.38. Over the past 10 years, this metric has ranged from a low of 35.60 to a high of 79.20. The Drug Manufacturers industry median Gross Margin % is 48.46. Amarin's value of 39.37% is 18.8% below this industry median. Based on the distribution chart, Amarin ranks #412 out of 935 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Amarin has a GF Score™ of 54/100, reflecting its overall financial health beyond just this single metric.
How does Amarin's Gross Margin % compare to SCLX and MIRA?
According to the Drug Manufacturers industry distribution chart, Amarin ranks #412 out of 935 companies for Gross Margin %. This puts Amarin in the upper half of its industry. The industry median Gross Margin % is 48.46. Amarin's value of 39.37% is 18.8% below this benchmark. Historically, Amarin's own Gross Margin % has ranged from 35.60 to 79.20 over the past decade. While the company's 10-year median is 74.38 vs. the industry median of 48.46, Amarin has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.46, based on 935 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Amarin's current Gross Margin % of 39.37% is 18.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Amarin and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amarin's current Gross Margin % is 39.37%, which is 47% below median its own 10-year median of 74.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amarin stock overvalued right now?
Amarin (STU:EH3) has a current Gross Margin % of 39.37%. The stock's GF Value™ is €10.19, compared to a current price of €14.10 — trading 38.4% above its estimated fair value. The current Gross Margin % is 39.37%, which is 47% below median its 10-year median of 74.38 and 18.8% below the Drug Manufacturers industry median of 48.46. Amarin's overall GF Score™ is 54/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Amarin (STU:EH3), the current Gross Margin % is 39.37% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Amarin (STU:EH3) Overvalued in 2026?
Based on GuruFocus' analysis, Amarin stock appears to be overvalued.
The current stock price of €14.10 is trading 38.4% above its estimated GF Value™ of €10.19.
Key valuation signals for STU:EH3:
Gross Margin %: 39.37% (47% below median its 10-year median of 74.38)
GF Value™: €10.19 vs. price of €14.10 (38.4% above fair value)
Industry Position: 18.8% below the Drug Manufacturers median (#412 of 935)
No single metric tells the full story. See the STU:EH3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Amarin Corp PLC is a pharmaceutical company. The company is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa. The company focuses on treatments to stop cardiovascular disease causing death, by providing patients, doctors and investors with reliable cardiovascular treatment options. Geographically, the company derives maximum revenue from United States.
54GF Score
Get the complete analysis for STU:EH3
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:EH3 has been successfully added to your 
